JAGGED1 expression is associated with prostate cancer metastasis and recurrence

Sandro Santagata, Francesca Demichelis, Alberto Riva, Sooryanarayana Varambally, Matthias D. Hofer, Jeffery L. Kutok, Robert Kim, Jeffery Tang, James E. Montie, Arul M. Chinnaiyan, Mark A. Rubin*, Jon C. Aster

*Corresponding author for this work

Research output: Contribution to journalArticle

272 Scopus citations

Abstract

Recent studies suggest that NOTCH signaling can promote epithelial-mesenchymal transitions and augment signaling through AKT, an important growth and survival pathway in epithelial cells and prostate cancer in particular. Here we show that JAGGED1, a NOTCH receptor ligand, is significantly more highly expressed in metastatic prostate cancer as compared with localized prostate cancer or benign prostatic tissues, based on immunohistochemical analysis of JAGGED1 expression in human tumor samples from 154 men. Furthermore, high JAGGED1 expression in a subset of clinically localized tumors was significantly associated with recurrence, independent of other clinical parameters. These findings support a model in which dysregulation of JAGGED1 protein levels plays a role in prostate cancer progression and metastasis and suggest that JAGGED1 may be a useful marker in distinguishing indolent and aggressive prostate cancers.

Original languageEnglish (US)
Pages (from-to)6854-6857
Number of pages4
JournalCancer Research
Volume64
Issue number19
DOIs
StatePublished - Oct 1 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'JAGGED1 expression is associated with prostate cancer metastasis and recurrence'. Together they form a unique fingerprint.

  • Cite this

    Santagata, S., Demichelis, F., Riva, A., Varambally, S., Hofer, M. D., Kutok, J. L., Kim, R., Tang, J., Montie, J. E., Chinnaiyan, A. M., Rubin, M. A., & Aster, J. C. (2004). JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Research, 64(19), 6854-6857. https://doi.org/10.1158/0008-5472.CAN-04-2500